[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652398":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":48,"collaborators":24,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":24,"studyType":65,"phases":66,"briefSummary":69,"conditions":70,"keywords":82,"overallStatus":86,"whyStopped":24,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Korro Bio, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"KRRO-121","EXPERIMENTAL","KRRO-121 is a GalNAc-conjugated RNA-editing oligonucleotide that recruits endogenous hepatic ADAR to edit mRNA, producing a de novo glutamine synthetase (GS) protein resistant to feedback-driven proteasomal degradation. By stabilizing hepatic GS, KRRO-121 augments ammonia clearance capacity independently of the underlying urea cycle enzyme defect.",[13],"Drug: KRRO-121",{"label":15,"type":16,"description":15,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","KRRO-121, subcutaneous injection",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Placebo, subcutaneous injection",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Nucleus Network Pty Ltd Study Director","CONTACT","(03) 8593 9801","name@name.com",[35],{"facility":36,"status":24,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":24},"Nucleus Network Pty Ltd","Melbourne","Victoria","3004","Australia","AU",{"type":43,"coordinates":44},"Point",[45,46],144.96332,-37.814,{"lat":46,"lon":45},{"type":49,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100652398","phase-1-phase-12-study-of-krro-121-in-healthy-volunteers-and-patients-with-ucd-100652398",false,"NCT07773246","Phase 1\u002F2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD","A Phase 1\u002F2, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KRRO-121 in Healthy Volunteers and Patients With Urea Cycle Disorders","ANCHOR","Inclusion Criteria:\n\n* Adult male or female participants, 18 to 65 years of age\n* Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and screening laboratory assessments, in the opinion of the Investigator.\n* Female participant of childbearing potential or male participant that is willing to use an approved, reliable means of contraception\n* Willing and able to provide signed written informed consent and to comply with all study requirements\n\nExclusion Criteria:\n\n* Any medical history that is clinically significant in the opinion of the Principal Investigator and Sponsor Medical Monitor\n* Any laboratory value at screening or predose on Day -1 outside the local laboratory reference range that is clinically significant in the opinion of the Principal Investigator and Sponsor Medical Monitor\n* Evidence of active systemic infection at Screening or Day 1 requiring antimicrobial, antiviral, or antifungal therapy\n* Use of any investigational drug or device within 3 months or 5 half-lives (whichever is longer) prior to Day 1\n* Concurrent participation in any other interventional clinical study",true,"ALL","18 Years","65 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67,68],"PHASE1","PHASE2","Phase 1\u002F2 Study of KRRO-121 is a randomized, placebo-controlled study in Healthy Volunteers (Phase 1 SAD and MAD) and Study Participants with Urea Cycle Disorders (Phase 2). The primary objective of the study is to evaluate the safety of KRRO-121.",[71,72,73,74,75,76,77,78,79,80,81],"Urea Cycle Disorders, Inborn","Urea Cycle Disorders","Ornithine Transcarbamylase (OTC) Deficiency","Arginase 1 Deficiency","NAGS Deficiency","Carbamylphosphate Synthetase I","Ornithine Transporter Mitochondrial 1","Argininosuccinate Synthase","Argininosuccinate Lyase Deficiency","N-acetyl Glutamate - Synthetase","Citrin Deficiency",[9,83,84,85],"stabilized variant of glutamine synthetase (GS)","ammonia clearance","RNA-editing","NOT_YET_RECRUITING","2026-08-18",{"date":89,"type":90},"2026-08-20","ACTUAL",{"date":92,"type":64},"2026-09",{"date":94,"type":64},"2027-09",{"name":5,"class":6},1]